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Abstract
Transforming growth factor-β (TGF-β) regulates all stages of mammary gland development, including the mainte-
nance of tissue homeostasis and the suppression of tumorigenesis in mammary epithelial cells (MECs). Interest-
ingly, mammary tumorigenesis converts TGF-β from a tumor suppressor to a tumor promoter through molecular
mechanisms that remain incompletely understood. Changes in integrin signaling and tissue compliance promote
the acquisition of malignant phenotypes in MECs in part through the activity of lysyl oxidase (LOX), which regulates
desmoplastic reactions and metastasis. TGF-β also regulates the activities of tumor reactive stroma and MEC
metastasis. We show here that TGF-β1 stimulated the synthesis and secretion of LOX from normal and malig-
nant MECs in vitro and in mammary tumors produced in mice. The ability of TGF-β1 to activate Smad2/3 was
unaffected by LOX inactivation in normal MECs, whereas the stimulation of p38 MAPK by TGF-β1 was blunted
by inhibiting LOX activity in malignant MECs or by inducing the degradation of hydrogen peroxide in both cell
types. Inactivating LOX activity impaired TGF-β1–mediated epithelial-mesenchymal transition and invasion in
breast cancer cells. We further show that increasing extracellular matrix rigidity by the addition of type I collagen
to three-dimensional organotypic cultures promoted the proliferation of malignant MECs, a cellular reaction that
was abrogated by inhibiting the activities of TGF-β1 or LOX, and by degrading hydrogen peroxide. Our findings
identify LOX as a potential mediator that couples mechanotransduction to oncogenic signaling by TGF-β1 and
suggest that measures capable of inactivating LOX function may prove effective in diminishing breast cancer
progression stimulated by TGF-β1.
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Introduction
Transforming growth factor-β (TGF-β) is a multifunctional cytokine
that regulates mammary gland development, as well as suppresses
mammary tumorigenesis [1,2]. In normal mammary epithelial cells
(MECs), TGF-β acts as a tumor suppressor by inducing apoptosis
and cell cycle arrest and by stimulating cellular differentiation. How-
ever, during breast cancer progression, TGF-β deviates from its role
as a tumor suppressor to ultimately acquire tumor promoting func-
tions, including the ability to induce breast cancer cell proliferation,
invasion, and metastasis in part through the stimulation of epithelial-
mesenchymal transition (EMT) [3,4]. The molecular mechanisms
that engender this switch in TGF-β function during tumorigenesis
are not well defined. Signaling through Smad2/3 generally is associated
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with cytostasis and maintenance of normal epithelial homeostasis.
However, TGF-β also signals through non–Smad-mediated pathways,
such as ERK1/2 (extracellular-regulated protein kinase1/2), p38MAPK
(p38 mitogen-activated protein kinase), JNK (c-Jun N-terminal protein
kinase), PI3K (phosphoinositide-3-kinase), NF-κB (nuclear factor-κB),
and Akt [2,3,5]. Indeed, we recently showed that αvβ3 integrin interacts
with the TGF-β type II receptor (TβR-II), leading to its phosphoryla-
tion by Src at Tyr284 and subsequent activation of p38 MAPK [6–8].
Collectively, these events enable TGF-β to stimulate breast cancer
growth, invasion, and metastasis. In fact, studies by our group [4,6–9]
and others [5] support the notion that inappropriate imbalances be-
tween canonical (i.e., Smad2/3–dependent) versus noncanonical (i.e.,
Smad2/3–independent) TGF-β pathways underlie its acquisition of
oncogenic function during tumor progression.
Lysyl oxidase (LOX) is a copper-dependent amine oxidase that cat-
alyzes the cross-linking of collagens and elastin in the extracellular
matrix (ECM). LOX belongs to a five member gene family consisting
of LOX, LOX-like 1 (LOXL1), LOXL2, LOXL3, and LOXL4, all of
which play important roles in regulating ECM remodeling and cel-
lular homeostasis [10,11]. In addition, elevated LOX activity is asso-
ciated with the acquisition of increased ECM tension and stiffness
in developing mammary tumors, a reaction that enhances integrin-
mediated mechanotransduction coupled to increased breast cancer
cell invasion and dissemination from hypoxic primary tumors [12–
17]. Clinically, the aberrant expression of LOX, LOXL, and LOXL2
correlates with increased malignancy and invasiveness in human tu-
mors, including those of the breast [16–18]. Along these lines, hy-
drogen peroxide produced as a byproduct of LOX-mediated collagen
and elastin cross-linking stimulates Rac1 activity by promoting the
assembly of p130Cas/Crk/Dock180 complexes [19]. Thus, LOX
seems critical in governing the transition of tumors from indolent
to aggressive disease states through the combined actions of its
ECM cross-linking activities, and its production of the potential sec-
ond messenger, hydrogen peroxide. Thus, chemotherapeutic target-
ing of LOX may one day improve the clinical course of metastatic
breast cancer patients.
Given the parallels between LOX and TGF-β in regulating ECM
dynamics and promoting mammary tumorigenesis, we sought to de-
termine the role of LOX in regulating oncogenic TGF-β1 signaling
and its coupling to EMT in normal and malignant MECs.
Materials and Methods
Cell Lines and Lentiviral Vectors
Normal murine mammary gland epithelial cell (NMuMG) and
metastatic 4T1 cells were cultured as previously described [20], as
were human MCF10ACA1a breast cancer cells [21] and human
293T embryonic kidney cells [22]. Lentiviral particles encoding for
scrambled (i.e., nonsilencing shRNA) or murine LOX shRNA (Thermo
Scientific, Huntsville, AL) were prepared as described previously [20].
The extent of LOX deficiency was monitored by immunoblot analysis
using anti-LOX antibody (1:200; Santa Cruz Biotechnology, Santa
Cruz, CA). A constitutively active LOX construct, LOX-32 [23], was
synthesized by polymerase chain reaction (PCR), amplifying mature
and catalytically active human LOX (nucleotides 505-1251) using oli-
gonucleotides containingHind III (N-terminus) andXho I (C-terminus)
restriction sites. The resulting PCR product was ligated into corre-
sponding sites in the pSecTag B vector (Invitrogen, Carlsbad, CA),
which C-terminally tagged the LOX-32 complementary DNA (cDNA)
with Myc- and (His)6-tags and appended the Igκ leader sequence to
its N-terminus. The resulting LOX-32 cDNA was sequenced in its
entirety on a DNA sequencing machine (3730; Applied Biosystems,
Carlsbad, CA).
Immunoblot Analyses
LOX activity was inhibited by pretreating MECs with the irrevers-
ible LOX inhibitor, β-aminopropionitrile (βAPN; 300 μM), or with
the hydrogen peroxide metabolizer, catalase (400 U/ml). Quiescent
NMuMG or 4T1 cells were incubated for varying times in the ab-
sence or presence of TGF-β1 (5 ng/ml; R&D Systems, Minneapolis,
MN) and, subsequently, were lysed and solubilized on ice in buffer
H/Triton X-100 [24]. Clarified whole-cell extracts and conditioned
medium collected from these cells before their lysis was resolved
through 10% SDS-PAGE gels, transferred electrophoretically to ni-
trocellulose membranes, and blocked in 5% milk before incubating
with the following primary antibodies (dilutions): 1) LOX (1:200;
Santa Cruz Biotechnology), 2) E-cadherin (1:500; BD Biosciences,
San Jose, CA), 3) phospho-Smad2 (1:1000; Cell Signaling, Danvers,
MA), and 4) phospho-p38 MAPK (1:500; Cell Signaling). The
resulting immunocomplexes were visualized by enhanced chemi-
luminescence, and differences in protein loading were monitored
by reprobing stripped membranes with anti–β-actin (1:1000; Santa
Cruz Biotechnology).
Cell Biological Assays
The effect of antagonizing LOX activity on various TGF-β1–
stimulated activities in NMuMG, 4T1, or MCF10ACa1a cells was
determined as follows: 1) cell proliferation in three-dimensional or-
ganotypic cultures using either ImageJ quantitation or CellTiter 96
AQueous One Solution Cell Proliferation Assay (MTS) according to
the manufacturer’s recommendations (Promega, Madison, WI), 2)
cell invasion induced by 2% serum using 25,000 cells/well in a
modified Boyden chamber coated with Matrigel (1:25 dilution) as
described [25], 3) gene expression using 30,000 cells/well in a syn-
thetic p3TP-luciferase reporter gene assay as described [25], and 4)
p38 MAPK phosphorylation induced by expression of a constitu-
tively active MKK6 as described [26]. In addition, the ability of
TGF-β1 stimulation and LOX inhibition to alter the actin cytoskeleton
was monitored using direct TRITC-phalloidin immunofluorescence
as described [27]. In some cases, the MECs cells were pretreated for
30 minutes with either βAPN (300 μM) or catalase (400 U/ml) before
addition of TGF-β1 (5 ng/ml) for 0 to 48 hours at 37°C.
Lastly, total RNA was isolated from NMuMG and 4T1 cells using
the RNeasy Plus Mini Kit according the manufacturer’s recommen-
dations (Qiagen, Valencia, CA). Afterward, cDNA were synthesized
using iScript cDNA Synthesis System (BioRad, Hercules, CA), and
semiquantitative real-time PCR was conducted using iQ SYBR
Green (BioRad) as described [28]. In all cases, differences in RNA
concentration were controlled by normalizing individual gene signals
to their corresponding GAPDH RNA signals. The oligonucleotide
primer pairs used were as follows: 1) LOX forward 5′-TGCCAGTG-
GATTGATATTACAGATGT and reverse 5′-AGCGAATGTCA-
CAGCGTA CAA; 2) E-cadherin forward 5′-CCCTACATACACT-
CTGGTGGTTCA and reverse 5′-GGCATCATC ATCGGTCAC-
TTTG; 3) N-cadherin forward 5′-CCCCCCAAGTCCAACATTTC
and reverse 5′-CGCCG TTTCATCCATACCAC; 4) cytokeratin 19
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Figure 1. TGF-β1 and EMT stimulate the expression and secretion of LOX in normal and malignant MECs. (A) Shown are representative
images of TGF-β1–treated NMuMG cells that have undergone EMT (top panel). TGF-β1 (5 ng/ml) stimulation of EMT in NMuMG cells
induced their expression of LOX as determined by semiquantitative real-time PCR. Individual transcript signals were normalized to
GAPDH. Data are the mean (±SE; n = 3) fold expression of LOX transcripts relative to pre-EMT NMuMG cells. *P < .05. (B) NMuMG
and 4T1 cells were incubated in the absence or presence of TGF-β1 (5 ng/ml) for 24 hours, at which point alterations in the actin cy-
toskeleton were monitored by TRITC–phalloidin immunofluorescence. Insets: magnified views of boxed regions. Data are representative
images from three independent experiments. (C) TGF-β1 (5 ng/ml) stimulated LOX production and secretion from NMuMG and 4T1 cells
as determined by immunoblot analysis conditioned medium (C) or detergent-solubilized whole cell extracts (L) with anti-LOX antibodies.
Differences in protein loading were monitored by immunoblot analysis for β-actin. Data are representative images from three indepen-
dent experiments.
Figure 2. TGF-β1 activates p38 MAPK through a hydrogen peroxide–dependent pathway in normal MECs. NMuMG cells were transiently
transfected with the TGF-β1–responsive reporter gene, p3TP-luciferase (A) or pSBE-luciferase (B), and with pCMV–β-gal. Afterward, the
transfectants were stimulated with TGF-β1 (5 ng/ml) in the absence or presence of βAPN (300 μM) or catalase (400 U/ml). Luciferase
activity was measured and normalized to β-gal. Data are the mean (±SE; n = 3). (C) Quiescent NMuMG cells were pretreated with βAPN
(300 μM), hydrogen peroxide (H2O2, 1 mM), or catalase (400 U/ml) as indicated and, subsequently, were stimulated with TGF-β1 (5 ng/ml)
for 30 minutes. The phosphorylation and expression levels of Smad2 and p38 MAPK were monitored by immunoblot analysis with
phospho-specific antibodies, and differences in protein loading were monitored by reprobing stripped membranes with antibodies
against β-actin. Shown are representative images from three independent experiments. (D) Four unique shRNA sequences targeting
LOX (sh#1–sh#4) were stably expressed in NMuMG cells and differences in LOX expression were analyzed by immunoblot analysis
with anti-LOX antibodies to detect mature LOX. Scram indicates scrambled shRNA. β-Actin immunoreactivity is provided as a loading
control. (E) Quiescent scrambled (Scram) and LOX-deficient (sh#4) NMuMG cells were stimulated with TGF-β1 (5 ng/ml) for 30 min, at
which point the phosphorylation and expression of Smad2 and p38 MAPK were monitored by immunoblot analysis as described in B.
Shown are representative images from three independent experiments. Scrambled (Scram) and LOX-deficient (sh#4) NMuMG cells
were transiently transfected with p3TP-luciferase (F) or pSBE-luciferase (G) pCMV–β-gal and, subsequently, were stimulated with
TGF-β1 (5 ng/ml) as described in A. Data are the mean (±SE; n = 3).
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forward 5′-TTGGGTCAGGGGGTGTTTTC and reverse 5′-TT-
CTCATTGCCAGACAGCAGC; 5) vimentin forward 5′-CAAGT-
CCAAGTTTGCTGACCTCTC and reverse 5′-CTCTTCCATCT-
CACGCATCTGG; 6) fibronectin III forward 5′-ACAACAACCC-
CAA GGAGAAG and reverse 5′-GCATCCTCTCTTCTGGTTCTG;
and 7) GAPDH forward 5′-CAACTTT GGCATTGTGGAAG-
GGCTC and reverse 5′-GCAGGGATGATGTTCTGGGCAGC.
LOX Immunohistochemistry
Archival 4T1 tumors that expressed GFP, WT-TGF-β type II re-
ceptor (TβR-II), or Y284F–TβR-II [8] were sectioned for histopath-
ologic analysis in the Pathology Core at the University of Colorado
Cancer Center. Afterward, LOX immunohistochemistry was per-
formed as described [8] using two independent preparations of anti-
LOX antibodies (1:50; Santa Cruz Biotechnology or Payne et al.
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[23]). Negative staining controls in all experiments entailed the pro-
cessing of adjacent samples in the absence of added primary anti-
LOX antibodies.
Three-dimensional Organotypic Cultures
Three-dimensional organotypic cultures were performed using the
“on-top” method as described [29]. Briefly, 4T1 cells were cultured
in either 48-well plates or 8-well chamber slides on Cultrex cushions
(100%; Trevigen, Gaithersburg, MD) in complete medium supple-
mented with 5% Cultrex. ECM rigidity in these organotypic cultures
was increased by adding type I collagen (3 mg/ml; BD Biosciences)
to Cultrex cushions before their solidification. Where indicated, the
MECs were treated with TGF-β1 (5 ng/ml), or the TGF-β type I
receptor (TβR-I) antagonist, TβR-I Inhibitor II (Calbiochem, San
Diego, CA). Cell growth and acinar formation were monitored by
bright-field microscopy. Measuring the secretion of TGF-β1 from
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4T1 acinar structures was accomplished using a TGF-β1 ELISA assay
(ElisaTech, Aurora, CO) as described [30].
To monitor alterations in E-cadherin localization, 4T1 acinar struc-
tures were stained with E-cadherin antibodies (BD Biosciences). Briefly,
4T1 organoids were propagated for 5 days, at which point they were
rinsed with PBS supplemented with CaCl2 (0.5 mM) and MgCl2
(0.9 mM) before fixation in 4% paraformaldehyde/PBS. Afterward,
the organoids were permeabilized with 0.1% Triton X-100/PBS for
5 minutes, thoroughly washed with PBS, and, subsequently, were
blocked in 1% BSA containing 5% goat serum for 1 hour at room tem-
perature before overnight incubation with anti–E-cadherin antibodies
(1:250 dilution) at room temperature. The next morning, the orga-
noids were washed and incubated sequentially for 1 hour with biotin-
conjugated anti-mouse IgG ( Jackson ImmunoResearch, West Grove,
PA), followed by Texas Red streptavidin D (Vector, Burlingame, CA).
Afterward, the stained organoids were mounted using ProLong Gold
Antifade mounting medium that contained DAPI (4′,6-diamidino-2-
phenylindole (Invitrogen), and the resulting images were captured on a
LeicaDM5000microscope (40×; LeicaMicrosystems, Bannockburn, IL).
Statistical Analysis
Statistical values were defined using an unpaired Student’s t test,
where P < .05 was considered significant.
Results
TGF-β1 and EMT Stimulate the Expression and Secretion of
LOX in Normal and Malignant MECs
Normal polarized NMuMG cells undergo EMT in response to
TGF-β1 and, in doing so, readily acquire a fibroblastoid-like morphol-
ogy (Figure 1, A and B). Interestingly, this same EMT protocol re-
sulted in the significant synthesis of LOX transcripts in post-EMT
NMuMG cells compared with their unstimulated counterparts (Fig-
ure 1A, bottom panel ). In addition, TGF-β1 also elevated the expression
of LOXL1, LOXL2, and LOXL3 in NMuMG cells that underwent
EMT (data not shown), suggesting that TGF-β1 functions as a gen-
eral regulator of LOX family member expression in normal MECs.
Because LOX clearly showed the highest induction by TGF-β1 and
promotes breast cancer progression [10,13,16,17,23], we restricted
our analyses solely to LOX for the remainder of the studies reported
herein. The ability of TGF-β1 to stimulate EMT not only was re-
stricted to NMuMG cells but also transpired in metastatic 4T1 cells
(Figure 1B) [4,7,9,20]. Moreover, we observed TGF-β1 to also stim-
ulate the synthesis and secretion mature LOX (32 kDa) from normal
(i.e., NMuMG) and metastatic (i.e., 4T1) MECs as measured by
immunoblotting the conditioned medium and whole-cell extracts
prepared from these cell types (Figure 1C ). Collectively, these find-
ings establish TGF-β1 as an inducer of LOX expression, secretion,
and proteolytic processing (i.e., an inducer of LOX activation) in
normal and malignant MECs. Our results also suggest that upregu-
lated LOX expression may play a role in regulating the malignancy
of MECs, particularly their response to TGF-β1.
TGF-β1 Regulates EMT in Normal MECs through a
LOX- and Hydrogen Peroxide–Dependent Pathway
We [4,6–8,31] and others [32–36] have shown the essential func-
tion of canonical (e.g., Smad2/3) and noncanonical (e.g., p38 MAPK)
TGF-β1 effectors in mediating its stimulation of EMT in normal and
malignant MECs. To determine the impact of LOX on TGF-β1–
mediated activation of Smad2/3 and p38 MAPK, we first treated nor-
mal NMuMG cells with the irreversible competitive LOX inhibitor,
βAPN, which has been shown to specifically inhibit the catalytic
activity of LOX [10,11,37] and several LOXL family members
[11,18]. In complementary approaches, we also administered catalase
to these cells to degrade the LOX second messenger, hydrogen perox-
ide [17], or stably transduced them with shRNA against LOX to de-
plete its expression. Figure 2 shows that these experimental conditions
failed to alter the transcriptional activity and phosphorylation of
Smad2/3 stimulated by TGF-β1, as did depleting LOX expression
in these MECs by their transduction with shRNA against LOX (Fig-
ures 2, A–G, and W1). Interestingly, catalase administration inhibited
TGF-β1 stimulation of p38 MAPK in NMuMG cells (Figure 2C ),
thereby implicating hydrogen peroxide as a mediator of p38 MAPK ac-
tivation in NMuMG cells. In stark contrast, we observed both βAPN
administration and LOX deficiency to elevate p38 MAPK phosphor-
ylation in resting NMuMG cells (Figure 2, C and E). These findings
suggest that disrupting LOX expression and activity may elicit a stress
response in normal MECs. Alternatively, these results may point to-
ward the activities of other LOXL family members in mediating the
ability of TGF-β1 to stimulate p38 MAPK in LOX-deficient MECs.
In light of the above results and those linking TGF-β1–driven EMT
to elevated LOX expression (Figure 1), we also examined the role of
LOX in mediating EMT stimulated by TGF-β1. As such, adminis-
tration of either βAPN or catalase (Figure 3A) or transduction with
shRNA against LOX (Figure 3B) attenuated the formation of stress
Figure 3. TGF-β1 regulates EMT in normal MECs through a LOX- and hydrogen peroxide–dependent pathway. (A) NMuMG cells were
incubated in the absence or presence of either βAPN (300 μM) or catalase (400 U/ml) while undergoing EMT stimulated by TGF-β1
(5 ng/ml). Arrowheads show strong actin fibers localized to focal adhesions in diluent-treated cells stimulated with TGF-β1 and, conversely,
stunted actin fibers in cells treated with βAPN or catalase. (B) Parental (scram) or LOX-deficient (shLOX#3 and shLOX#4) NMuMG cells
were stimulated by TGF-β1 (5 ng/ml) to induce EMT. Arrowheads show strong actin fibers localized to focal adhesions in Scram cells
stimulated with TGF-β1 and, conversely, the presence of stunted actin fibers in LOX-deficient cells. Shown are representative images from
three independent experiments. (C) NMuMG cells were stimulated to undergo EMT by TGF-β1 (5 ng/ml) in the absence (i.e., diluent; Dil) or
presence of either βAPN (300 μM) or catalase (400 U/ml; Cat). Altered expression of cytokeratin 19, E-cadherin, N-cadherin, vimentin, or
fibronectin mRNA was determined by semiquantitative real-time PCR. Individual transcript signals were normalized to GAPDH. Data are the
mean (±SE; n = 3) transcript levels normalized to corresponding unstimulated controls. *P < .05. **P < .05. (D and E) Altered E-cadherin
(E-cad) expression was monitored by immunoblot analysis detergent-solubilized whole-cell extracts with anti–E-cadherin antibodies. Pro-
tein loading was controlled with anti–β-actin antibodies. Shown are representative images from two independent experiments. Accompa-
nying graphs show the densitometric mean (±SE; n = 2) relative to corresponding basal cells. *P < .05.
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fibers stimulated by TGF-β1, suggesting that targeting LOX activ-
ity can diminish EMT stimulated by TGF-β1. Accordingly, TGF-β1
induced NMuMG cells to acquire an EMT phenotype that included
attenuated expression of the epithelial markers cytokeratin 19 and
E-cadherin and augmented expression of the mesenchymal cell mark-
ers, N-cadherin, vimentin, and fibronectin (Figure 3C). Pharmacolog-
ical targeting of LOX family members using βAPN or administration of
catalase both significantly stimulated the expression of cytokeratin-19
and E-cadherin compared with their diluent treated counterparts, sug-
gesting that the production of hydrogen peroxide by LOX family mem-
bers selectively suppressed the expression of epithelial markers, and
perhaps, sensitized cells to undergo EMT in response to TGF-β1. Simi-
larly, βAPN treatment led to a significant reduction in vimentin and fi-
bronectin expression comparedwith diluent-treated controls (Figure 3C).
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Interestingly, LOX deficiency failed to fully recapitulate these responses
(data not shown), suggesting that other βAPN-sensitive LOXL members
may play a role during EMT induced by TGF-β1. Along these lines,
βAPN treatment or LOX deficiency significantly inhibited the ability
of TGF-β1 to downregulate E-cadherin protein expression in transi-
tioning NMuMG cells (Figure 3, D and E). Thus, these findings sug-
gest that LOX and its LOXL relatives sensitize transitioning MECs to
complete the EMT program when stimulated by TGF-β1.
LOX Regulates Breast Cancer Cell p38 MAPK Activation
and Invasion Stimulated by TGF-β1
Previous findings by our group demonstrated that β3-integrin inter-
acts physically with TβR-II leading to its phosphorylation on Y284 by
Src and the subsequent activation of p38 MAPK that drives the pul-
monary metastasis of 4T1 tumors [6–8]. Activation of this oncogenic
TGF-β signaling cascade is amplified by overexpression of wild-type
(WT) TβR-II in 4T1 cells and, more importantly, completely inacti-
vated by their overexpression of Y284F–TβR-II mutants [8]. Histo-
pathologic analysis of sections obtained from these same tumors
revealed that LOX expression was upregulated significantly and specif-
ically in 4T1 tumors that possessed enhanced oncogenic TGF-β sig-
naling (i.e., WT–TβR-II–expressing 4T1 tumors) but not in 4T1
tumors engineered to express either GFP (i.e., parental controls) or
Src-resistant Y284F–TβR-II mutants (Figure 4A). Thus, LOX expres-
sion was upregulated in late-stage mammary tumors in response to
oncogenic TGF-β signaling. Given the importance of p38 MAPK in
driving breast cancer progression stimulated by TGF-β, we admin-
istered βAPN or catalase to 4T1 cells before their stimulation with
TGF-β1. Similar to NMuMG cells (Figure 2), both experimental treat-
ments failed to alter the coupling of TGF-β1 to Smad2/3 in 4T1 cells
(Figures 4, B–D, and W1). However, unlike NMuMG cells, adminis-
tration of either βAPN or catalase significantly reduced the coupling of
TGF-β1 to p38 MAPK in 4T1 cells (Figure 4D), suggesting that LOX
and hydrogen peroxide may play an expanded role in regulating TGF-
β1 signaling in metastatic MECs compared with their normal counter-
parts. In addition, transient overexpression of constitutively active
LOX-32 in these cells increased basal p38 MAPK activation but failed
to further augment p38 MAPK activation by TGF-β1 (Figure W2).
Even more surprisingly, depleting 4T1 cells of LOX expression
(Figure 4E) not only attenuated TGF-β1 stimulation of p38 MAPK
(Figure 4F ) but also significantly reduced Smad2/3 transcriptional ac-
tivity and phosphorylation of Smad2 induced by TGF-β1 (Figure 4, E–
H ). This reduction in Smad2/3 phosphorylation and transcriptional
activity cannot be attributed to enhanced activation of p38 MAPK,
which can phosphorylate the linker region of Smad2/3 [38]. For in-
stance, Figure W3 shows that overexpression of constitutively active
MKK6, which significantly enhanced p38 MAPK activation, had no
effect on the coupling of TGF-β1 to Smad2/3 phosphorylation and re-
porter gene expression in 4T1 cells. Functionally, administration of cat-
alase significantly inhibited 4T1 cell invasion stimulated by TGF-β1,
whereas inclusion of either βAPN or catalase significantly antagonized
the ability of TGF-β1 to induce the invasion of human MCF10ACA1a
cells (Figure 4I ), which were previously established as a model for
metastatic progression regulated by TGF-β [21]. Similar to βAPN treat-
ment, LOX deficiency failed to affect the extent of 4T1 cell invasion
stimulated by TGF-β1 (data not shown). These findings establish
TGF-β1 as an inducer of LOX expression in vivo and suggest that up-
regulated expression LOX or another LOXL family member and/or hy-
drogen peroxide production may regulate the malignancy of MECs in
response to TGF-β1, including its ability to induce breast cancer cell
invasion.
Mechanotransduction Induces Autocrine TGF-β1 Signaling
Coupled to MEC Proliferation
Tissue compliance and ECM rigidity play vital roles in mediating
cellular organization during embryogenesis and in maintaining tissue
homeostasis in adult tissues [12]. Moreover, increased tissue tension
resulting from desmoplastic and fibrotic stromal reactions is associated
with mammary tumorigenesis and its progression to metastasis, activ-
ities that have also been attributed to LOX-dependent cross-linking of
collagen to elastin during neoplastic progression [12,14,15,39]. At
present, the role of tissue rigidity and mechanotransduction in regu-
lating the behaviors of MECs to TGF-β remains unknown. As such,
we compared the response of 4T1 cells to TGF-β1 when propagated
under compliant and rigid culture conditions. Figure 5A shows that
in traditional two-dimensional cultures, which are extremely rigid
Figure 4. LOX regulates breast cancer cell p38 MAPK activation and invasion stimulated by TGF-β1. (A) Elevated oncogenic TGF-β1
signaling (i.e., WT–TβR-II expression) greatly accelerates the growth and pulmonary metastasis of 4T1 tumors in mice [8]. LOX immuno-
histochemistry performed on these same tumor slices showed that TGF-β1 signaling significantly induced the expression of LOX expres-
sion in WT–TβR-II–expressing 4T1 tumors compared with their GFP- or Y284F–TβR-II–expressing counterparts. Data are representative
images from two independent experiments. WT indicates wild-type. 4T1 cells were transiently transfected with p3TP-luciferase (B) or
pSBE-luciferase (C) and pCMV–β-gal and, subsequently, were stimulated with TGF-β1 (5 ng/ml) in the absence or presence of βAPN
(300 μM) or catalase (400 U/ml). Luciferase activity was measured and normalized to β-gal. Data are the mean (±SE; n = 3). (D) Qui-
escent 4T1 cells were pretreated with βAPN (300 μM), hydrogen peroxide (H2O2, 1 mM), or catalase (400 U/ml) as indicated and, sub-
sequently, were stimulated with TGF-β1 (5 ng/ml) for 30 minutes. The phosphorylation and expression of Smad2 and p38 MAPK was
monitored by immunoblot analysis, and differences in protein loading were monitored by reprobing stripped membranes with anti-
bodies against β-actin. Shown are representative images from three independent experiments. (E) Three unique shRNA sequences
targeting LOX (sh#2–sh#4) were stably expressed in 4T1 cells, and differences in LOX expression were analyzed by immunoblot analysis
with anti-LOX antibodies. Scram indicates scrambled shRNA. β-Actin immunoreactivity is provided as a loading control. (F) Quies-
cent scrambled (Scram) and LOX-deficient (sh#4) 4T1 cells were stimulated with TGF-β1 (5 ng/ml) for 30 min, at which point the
phosphorylation status and expression of Smad2 and p38 MAPK were monitored by immunoblot analysis as described in D. Shown
are representative images from three independent experiments. Scrambled (Scram) and LOX-deficient (sh#4) 4T1 cells were transiently
transfected with p3TP-luciferase (G) or pSBE-luciferase (H) and pCMV–β-gal and, subsequently, were stimulated with TGF-β1 (5 ng/ml) as
described in A. Data are the mean (±SE; n = 3). (I) 4T1 or MCF10ACA1a (CA1a) cells were incubated in the absence or presence of
either βAPN (300 μM) or catalase (400 U/ml) while undergoing invasion through synthetic basement membranes in response to TGF-β1
(5 ng/ml). Data are the mean (±SE; n = 3) invasion relative to that stimulated by TGF-β1. *P < .05.
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[12], TGF-β1 readily promoted the proliferation of 4T1 cells. In stark
contrast, propagating 4T1 cells in compliant three-dimensional or-
ganotypic cultures was sufficient to restore the cytostatic activities of
TGF-β1 in these malignant MECs, which normally fail to undergo
growth arrest in response to TGF-β1 (Figure 5A) [4,7–9,28,40–43].
Importantly, supplementing these three-dimensional organotypic cul-
tures with type I collagen to initiate mechanotransduction uncoupled
TGF-β1 from the regulation of cell cycle progression in 4T1 cells
(Figure 5A). Thus, ECM tension and rigidity clearly alter how MECs
respond to the cytostatic activities of TGF-β1 [20]. Along these lines,
we also inhibited TGF-β1 signaling in 4T1 cells by treating them with
a small-molecule TβR-I antagonist, TβR-I Inhibitor II [28,40–43],
and subsequently monitored alterations in their growth and morphol-
ogy. As shown in Figure 5B, 4T1 organoids propagated in compliant
cultures formed abnormal acinar structures, which underwent dra-
matic expansion and branching in response to increased ECM rigidity.
Interestingly, the growth and branching of 4T1 organoids elicited by
mechanotransduction were abrogated by inactivating TGF-β1 signal-
ing, which restored the formation of spherical acinar structures (Fig-
ure 5B). Consistent with the ability of compliant microenvironments
to reinstate cytostatic signaling by TGF-β1 (Figure 5A), inactivation of
TGF-β1 signaling in these cultures by treating them with the TβR-I
antagonist was sufficient to stimulate the growth and expansion of 4T1
organoids (Figure 5B). Thus, autocrine TGF-β1 signaling seems to
play a prominent role in regulating MEC response to TGF-β1 under
compliant and rigid ECM conditions. Accordingly, 4T1 (Figure 5C)
and MCF-7 (data not shown) organoids propagated under rigid ECM
conditions produced significantly more TGF-β1 compared with their
counterparts propagated under compliant ECM conditions. Taken to-
gether, these findings show for the first time that exposing late-stage
breast cancer cells to compliant ECM signals reinstates the cytostatic
activities TGF-β1 and, in effect, partially reestablishes the tumor sup-
pressing functions of TGF-β1 in malignant MECs.
Mechanotransduction Induces MEC Proliferation and
E-cadherin Redistribution in a LOX-Dependent Manner
To examine the specific contributions of LOX activity in regulating
MEC response to TGF-β, we again cultured 4T1 cells under compliant
or rigid ECM conditions with or without added βAPN or catalase.
Figure 6A shows that inhibiting LOX activity or degrading hydrogen
Figure 5. Mechanotransduction induces autocrine TGF-β1 signaling coupled to MEC proliferation. (A) 4T1 cells were in incubated the ab-
sence or presence of TGF-β1 (5 ng/ml) in two-dimensional tissue culture plastic or in three-dimensional organotypic cultures supplemented
without (i.e., compliant) or with type I collagen (3 mg/ml; rigid). Bright-field images were captured and used to quantitate cell proliferation
through ImageJ. Data are the mean (±SE; n = 3) proliferation relative to basal 4T1 cells. *P < .05. (B) Inhibition of TGF-β1 signaling by
administration of the TβR-I inhibitor (100 ng/ml) enhanced the growth of 4T1 cells in compliant three-dimensional organotypic cultures,
but inhibited their growth in rigid (3mg/ml type I collagen) three-dimensional organotypic cultures. Insets:magnified views of boxed regions.
Data are representative images from three independent experiments. (C) Conditioned medium harvested from compliant or rigid three-
dimensional organotypic cultureswas acidified to activate total TGF-β1. After sample neutralization, TGF-β1 concentrationswere determined
by ELISA analysis. Data are the mean (±SE; n = 3) TGF-β1 concentrations relative to those measured in compliant cultures. *P < .05.
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peroxide both significantly reduced the growth of 4T1 cells stimulated
by rigid ECM. Consistent with the effect of compliant ECM to re-
store cytostasis mediated by TGF-β1, these same experimental treat-
ments elicited little-to-no effect on the ability of 4T1 cells to undergo
growth arrest in response to TGF-β1 (Figure 6, A and B). Similarly,
LOX deficiency (Figure 4E) abrogated the ability of TGF-β1 to stim-
ulate the growth of 4T1 organoids in rigid ECM (Figure 7A) and,
instead, partially reestablished the cytostatic activities of TGF-β1 in met-
astatic MECs.
Finally, given the ability of LOX activity to suppress E-cadherin
expression (Figure 3) and given the ability of E-cadherin expression
to suppress the uncontrolled growth of cancer cells [44], we hypothe-
sized that LOX deficiency may suppress the growth of 4T1 organoids
by upregulating and stabilizing E-cadherin expression at the plasma
membrane. Accordingly, E-cadherin expression was readily detected
and localized to the cell surface in parental and LOX-deficient 4T1
organoids propagated under rigid culture conditions (Figure 7B). Im-
portantly, treating these same organoids with TGF-β1 resulted in the
complete loss of E-cadherin from the plasma membrane in parental
and scrambled shRNA-expressing 4T1 organoids, a reaction that was
not recapitulated in their LOX-deficient counterparts (Figure 7B).
Collectively, these findings suggest that LOX expression and activity
may be essential in linking the oncogenic activities of TGF-β1 and
mechanotransduction in breast cancer cells, presumably by regulating
the expression and localization of E-cadherin.
Discussion
Breast cancer is the second leading cause of cancer death in women.
Although the 5-year survival rate for women with localized disease is
high at 98%, this number drops precipitously to only 27% once the
primary tumor has metastasized [45]. For this reason, it is vitally im-
portant for science and medicine to enhance their understanding of
the processes that underlie breast cancer invasion and metastasis. It
has long been established that breast cancer development reflects a
loss-of-tissue organization and differentiation, factors that have more
recently been associated with increases in LOX expression and activ-
ity [46,47]. We show here that TGF-β and EMT both induce the
expression and secretion of LOX from normal and malignant MECs
and that mammary tumors engineered to house elevated TGF-β sig-
naling produced more LOX than did their parental counterparts,
which correlated with the ability of TGF-β to stimulate mammary
tumor growth and pulmonary metastasis [8]. Equally important,
we provide the first evidence that the manner in which MECs re-
spond to TGF-β can be regulated by tissue rigidity, which elicits
dramatic changes in MEC acinar morphology and growth in a
LOX- and hydrogen peroxide–dependent manner. Although the ex-
act mechanisms whereby tissue tension regulates TGF-β1 function
remain to be elucidated fully, it is tempting to speculate that en-
hanced ECM rigidity may promote the inappropriate clustering of
TGF-β receptors with integrins and other growth factor receptors,
thereby inducing amplified coupling of TGF-β to its noncanonical
effectors [48,49]. Accordingly, we demonstrated that antagonizing
LOX activity led to the diminished ability of TGF-β to stimulate
MEC invasion and EMT. Furthermore, we show that antagonizing
LOX activity partially uncoupled TGF-β1 from p38 MAPK activa-
tion in metastatic 4T1 cells, whereas only catalase administration
facilitated this event in normal NMuMG cells, suggesting that the
roles of LOX and hydrogen peroxide depend on the pathophysiology
of MECs.
Figure 6.Mechanotransduction inducesMEC proliferation in a LOX-
dependent manner. (A) LOX antagonism using βAPN (300 μM) or
catalase (400 U/ml) inhibited the ability of TGF-β1 to stimulate 4T1
cell growth in rigid three-dimensional organotypic cultures. Insets:
magnified views of boxed regions. Shown are representative images
from three independent experiments. (B) Accompanying data are
the mean (±SE; n = 3) proliferation relative to the growth of basal
cells in compliant cultures. *P < .05.
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Figure 7. LOX deficiency suppressesmechanotransduction and TGF-β1 stimulation ofMEC proliferation by restoring cell surface E-cadherin
expression. (A) Parental, scrambled (Scram), or LOX-deficient (sh#3 and sh#4) 4T1 cells were propagated in rigid three-dimensional organo-
typic cultures in the absence or presence of TGF-β1 (5 ng/ml) as indicated. Bright-field images were captured (top panel) and used to quan-
titate cell proliferation through ImageJ (bottom panel). Insets: magnified views of boxed regions. Data are the mean (±SE; n = 3)
proliferation relative to basal 4T1 cells. *P < .05. (B) Parental, scrambled (Scram), or LOX-deficient (sh#3 and sh#4) 4T1 cells were prop-
agated in rigid three-dimensional organotypic cultures as described in A and, subsequently, were processed to visualize the expression and
localization of E-cadherin by immunofluorescence. Corresponding nuclei were detected by inclusion of DAPI as indicated. Data are rep-
resentative images from three independent experiments.
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It is important to note that although our current findings support
an extracellular role of LOX in mediating the oncogenic activities of
TGF-β (i.e., catalase neutralizes hydrogen peroxide), we cannot ex-
clude the possibility that LOX may promote oncogenic TGF-β signal-
ing by acting intracellularly. Indeed, mature LOX has been detected
not only in the ECM but also in the cytoplasm (Figure 1) and nucleus
of malignant cells [10,11]; however, the identification of specific mo-
lecules capable of interacting with and/or being targeted by LOX in
either intracellular compartment remains to be elucidated fully [11].
Along these lines, LOX was shown to activate Src and promote cell
adhesion through a hydrogen peroxide–dependent mechanism [23].
We show here that administering catalase to degrade hydrogen perox-
ide prevented TGF-β from stimulating MEC proliferation, EMT, and
invasion (Figures 3–7) and from fully activating p38 MAPK (Figure 4).
Thus, hydrogen peroxide may function as a novel “second messenger”
for TGF-β in normal and malignant MECs. Collectively, our findings
suggest that LOX may play an important role in initiating the conver-
sion of TGF-β function from a suppressor to a promoter of mammary
tumorigenesis. At present, the specific players targeted by LOX and
hydrogen peroxide that affect TGF-β signaling remain an active and
important topic for future experimentation. In addition, it is unclear
what overlapping functions other LOX family members may play. Im-
portantly, LOXL2 is not inhibited by βAPN treatment and may com-
pensate for loss of LOX function [11,50], and in fact, both LOX and
LOXL2 mediate the ability of HIF-1α to suppress E-cadherin ex-
pression [51]. Thus, future studies need to dissect the relative con-
tribution of individual LOX family members to the initiation of
oncogenic TGF-β signaling and its coupling to canonical and non-
canonical effectors.
LOX plays a critical role during the formation of premetastatic
niches by stimulating collagen cross-linking and fibronectin synthe-
sis, leading to the recruitment of bone marrow–derived cells to meta-
static niches [13]. TGF-β has also been implicated in the recruitment
of immature bone marrow–derived cells to drive breast cancer metas-
tasis [52], which suggests a potential link between TGF-β and LOX
in regulating the formation of premetastatic niches. Interestingly, the
use of copper chelators in preclinical and phase 2 clinical trials has
shown some success in diminishing metastatic burden [53], findings
that are potentially important because LOX activity is absolutely de-
pendent on copper as one of its two cofactors (the other being lysyl
tyrosyl quinone [11]). Thus, it is plausible that the clinical success of
copper chelators to reduce tumor metastasis lies in their ability to
inhibit LOX activity and, consequently, perhaps to alleviate the onco-
genic activities of TGF-β as well. Along these lines, tumor hypoxia
predicts for poor prognosis and decreased survival of breast cancer pa-
tients, which is linked to hypoxia-induced expression of LOX and the
generation of metastatic niches in breast cancer patients [13,16,54].
These findings, together with those presented herein, support the idea
that LOX dictates how malignant MECs respond to the varied ac-
tivities of TGF-β, and as such, identify LOX as a novel participant
in oncogenic TGF-β1 signaling in late-stage mammary tumors. Thus,
chemotherapeutic targeting of LOX may offer new inroads to alleviate
breast cancer progression stimulated by TGF-β.
Lastly, the ability of LOX to cross-link collagen to elastin results in
increased tissue tension and ECM rigidity [12,15,39,55]. More re-
cently, ECM rigidity has been shown to play an important role in
breast cancer development, particularly their acquisition of invasive
and metastatic phenotypes [12,39,47,56]. The ability of normal
and malignant MECs to sense ECM stiffness transpires through in-
tegrins and other mechanotransducers, which in turn activate Src,
FAK, and the GTPases, Rho, Rac, and Cdc42 [46,47]. Importantly,
we identified an oncogenic TGF-β signaling axis comprised in part of
αvβ3 integrin, FAK, and Src that induces mammary tumor growth,
invasion, and metastasis in mice [4,8,9], as well as stimulates signif-
icant LOX expression in these same mammary tumors (Figure 4). We
speculate that tumor-initiated MECs evolve in compliant microen-
vironments that favor canonical Smad2/3 signaling stimulated by
TGF-β. The continued growth of the developing neoplasm enhances
ECM rigidity by upregulating TGF-β production (Figure 5) and
LOX expression (Figure 1), which may lead to the inappropriate for-
mation of integrin–TβR-II complexes [6–8]. Once formed, these
complexes are also likely to interact with other growth factor recep-
tors that presumably amplify the activation of noncanonical effectors
by TGF-β [57]. Ultimately, these adverse events culminate in the
ability of TGF-β to induce the acquisition of EMT, stem-like, and
metastatic phenotypes in malignant MECs, leading to their metasta-
sis at distant locales. Moreover, extending our findings to encompass
sites of micrometastases [13], which are predicted to possess compli-
ant ECM tension, leads us to propose that the cytostatic activities of
TGF-β may be partially reinstated at these newly seeded sites, per-
haps contributing to tumor dormancy. Over time, this vicious micro-
environmental cycle is repeated, leading to disease recurrence and
poor clinical outcomes in breast cancer patients harboring metastatic
disease. The basic tenets of this model are supported by the findings
presented herein (Figures 5–7), and as such, this model should serve
as a launching point for future studies aimed at identifying the indi-
vidual effectors operant in regulating ECM tension and TGF-β1
function in distinct breast cancer subtypes.
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Figure W1. Pharmacologic and genetic targeting of LOX fail to alter TGF-β1 stimulation of Smad3 phosphorylation in normal and ma-
lignant MECs. Quiescent NMuMG (A) and 4T1 (C) cells were pretreated with βAPN (300 μM), hydrogen peroxide (H2O2, 1 mM), or
catalase (400 U/ml) as indicated. Afterward, these MECs and their LOX-deficient (sh#4) counterparts (B, D) were stimulated with
TGF-β1 (5 ng/ml) for 30 minutes before monitoring changes in the expression (t-Smad2/3) and phosphorylation (p-Smad3) of Smad3
by immunoblot analysis. Differences in protein loading were assessed by reprobing stripped membranes with β-actin antibodies. Data
are representative images from three independent experiments. Scram indicates scrambled shRNA.
Figure W2. Expression of constitutively active LOX stimulates p38 MAPK in normal and malignant MECs. Human 293T (A), NMuMG (B), or
4T1 (C) cells were transiently transfected with constitutively active LOX (LOX32). Thirty-six hours after transfection, the conditioned me-
dium (CDM) was tumbled with Ni2+-agarose beads to capture recombinant LOX32 proteins (A, C) or was precipitated with trichloroacetic/
deoxycholate (B). Recombinant LOX32 protein expression was visualized by immunoblot analysis with anti-Myc antibodies. After collecting
CDM, the cells were incubated for 4 hours in serum-free medium before stimulation with TGF-β1 (5 ng/ml) for 30 minutes at 37°C as
indicated. The phosphorylation status of p38 MAPK was assessed by immunoblot analysis with phospho-specific p38 MAPK (p-p38MAPK)
antibodies, whereas differences in protein loading were monitored by reprobing stripped membranes with antibodies against p38 MAPK
(t-p38 MAPK) and β-actin. Data are representative images from two independent experiments.
Figure W3. Expression of constitutively active MKK6 activates p38 MAPK but has no effect on the coupling of TGF-β to Smad2/3 in
malignant MECs. 4T1 cells were transiently transfected overnight with p3TP-luciferase and pCMV–β-gal, together with either empty
vector (mock) or constitutively active MKK6 as indicated. Afterward, the cells were stimulated with TGF-β1 (5 ng/ml) for 24 hours, at
which point cell extracts were prepared for p38 MAPK and Smad2 immunoblot analysis (A) or luciferase and β-gal assays (B). Data are
representative images or the resulting luciferase activity (mean ± SE) from three independent experiments.
